• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Phase I clinical studies with cytotoxic drugs: pharmacokinetic and pharmacodynamic considerations.细胞毒性药物的I期临床研究：药代动力学和药效学考量
Br J Cancer. 1990 Feb;61(2):189-91. doi: 10.1038/bjc.1990.35.
2
Predicting Antitumor Effect of Deoxypodophyllotoxin in NCI-H460 Tumor-Bearing Mice on the Basis of In Vitro Pharmacodynamics and a Physiologically Based Pharmacokinetic-Pharmacodynamic Model.基于体外药效学和基于生理的药代动力学-药效学模型预测脱氧鬼臼毒素在荷 NCI-H460 肿瘤小鼠中的抗肿瘤作用。
Drug Metab Dispos. 2018 Jun;46(6):897-907. doi: 10.1124/dmd.117.079830. Epub 2018 Apr 4.
3
Evaluation of the efficiency of targeting of antitumor drugs: simulation analysis based on pharmacokinetic/pharmacodynamic considerations.抗肿瘤药物靶向效率评估：基于药代动力学/药效学考量的模拟分析
J Drug Target. 1996;3(6):443-53. doi: 10.3109/10611869609015964.
4
Pharmacokinetic/pharmacodynamic considerations for cancer patients undergoing hemodialysis.癌症患者血液透析时的药代动力学/药效学考虑因素。
Expert Opin Drug Metab Toxicol. 2017 Jun;13(6):617-623. doi: 10.1080/17425255.2017.1292252. Epub 2017 Feb 17.
5
Re: Antitumor efficacy testing in rodents.关于：啮齿动物的抗肿瘤疗效测试。
J Natl Cancer Inst. 2009 Nov 18;101(22):1592-3; author reply 1593-4. doi: 10.1093/jnci/djp356. Epub 2009 Oct 28.
6
PET screening of anticancer drugs. A faster route to drug/target evaluations in vivo.
Methods Mol Med. 2003;85:279-94. doi: 10.1385/1-59259-380-1:279.
7
Can pharmacokinetic and pharmacodynamic studies improve cancer chemotherapy?药代动力学和药效学研究能否改善癌症化疗？
Ann Oncol. 1994;5 Suppl 4:9-14; discussion 15. doi: 10.1093/annonc/5.suppl_4.s9.
8
[Preclinical studies for development of anti-cancer drugs: current and historical status and problems].[抗癌药物研发的临床前研究：现状、历史及问题]
Gan To Kagaku Ryoho. 1994 Oct;21 Suppl 3:302-9.
9
[Pharmacokinetic approach to the improvement of clinical predictability in the preclinical test for antitumor agents].[抗肿瘤药物临床前试验中提高临床可预测性的药代动力学方法]
Gan To Kagaku Ryoho. 1991 Jul;18(9):1449-56.
10
[Early clinical trial of antineoplastic agents--recent perspectives of pharmacological analysis in phase I study].
Gan To Kagaku Ryoho. 2001 Mar;28(3):411-4.

引用本文的文献

1
Cytotoxic Mechanism of Momilactones A and B against Acute Promyelocytic Leukemia and Multiple Myeloma Cell Lines.稻瘟菌素A和B对急性早幼粒细胞白血病和多发性骨髓瘤细胞系的细胞毒性机制
Cancers (Basel). 2022 Oct 4;14(19):4848. doi: 10.3390/cancers14194848.
2
Animal models and conserved processes.动物模型与保守过程。
Theor Biol Med Model. 2012 Sep 10;9:40. doi: 10.1186/1742-4682-9-40.
3
Pharmacokinetic studies in mice with ICI D0490, a novel recombinant ricin A-chain immunotoxin.使用新型重组蓖麻毒素A链免疫毒素ICI D0490对小鼠进行的药代动力学研究。
Br J Cancer. 1993 Jun;67(6):1310-5. doi: 10.1038/bjc.1993.243.
4
Dose response evaluation. Use of plasma concentration confidence intervals as a tool to predict optimal drug dose ratio.剂量反应评估。使用血浆浓度置信区间作为预测最佳药物剂量比的工具。
Clin Pharmacokinet. 1993 Jul;25(1):1-5. doi: 10.2165/00003088-199325010-00001.
5
Normalisation of anti-cancer drug dosage using body weight and surface area: is it worthwhile? A review of theoretical and practical considerations.
Cancer Chemother Pharmacol. 1993;32(6):411-8. doi: 10.1007/BF00685883.
6
Concentration-controlled trials. What does the future hold?浓度控制试验。未来会怎样？
Clin Pharmacokinet. 1995 Feb;28(2):93-9. doi: 10.2165/00003088-199528020-00001.

本文引用的文献

1
Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function.肾功能受损患者中顺式二氨（1,1-环丁烷二羧酸根）铂的药代动力学及剂量调整
Cancer Res. 1984 Nov;44(11):5432-8.
2
Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man.抗癌药物在小鼠、大鼠、仓鼠、狗、猴和人类中毒性的定量比较。
Cancer Chemother Rep. 1966 May;50(4):219-44.
3
Relation of preclinical toxicology to findings in early clinical trials.临床前毒理学与早期临床试验结果的关系。
Cancer Treat Rep. 1986 Jan;70(1):65-72.
4
Therapeutic response in phase I trials of antineoplastic agents.抗肿瘤药物一期试验中的治疗反应。
Cancer Treat Rep. 1986 Sep;70(9):1105-15.
5
The role of comparative pharmacokinetics in the planning of human dose escalation: the experience with diacetyldianhydrogalactitol.比较药代动力学在人体剂量递增计划中的作用：双乙酰双去水半乳糖醇的经验
Cancer Chemother Pharmacol. 1988;22(2):109-13. doi: 10.1007/BF00257306.
6
A phase I and pharmacokinetic study of amphethinile.安非他尼的I期和药代动力学研究。
Br J Cancer. 1988 Jun;57(6):623-7. doi: 10.1038/bjc.1988.142.
7
Comparative pharmacokinetics of cisplatin and three analogues in mice and humans.顺铂及其三种类似物在小鼠和人体中的比较药代动力学
Cancer Res. 1987 Dec 1;47(23):6297-301.
8
Preclinical pharmacology of the anthrapyrazole analog oxantrazole (NSC-349174, piroxantrone).蒽吡唑类似物奥沙蒽酮（NSC-349174，吡罗蒽醌）的临床前药理学
Cancer Chemother Pharmacol. 1989;23(4):213-8. doi: 10.1007/BF00451644.
9
Quantitative prediction of drug toxicity in humans from toxicology in small and large animals.通过大小动物毒理学对人类药物毒性进行定量预测。
Cancer Res. 1975 May;35(5):1354-64.

Phase I clinical studies with cytotoxic drugs: pharmacokinetic and pharmacodynamic considerations.

作者信息

Newell D R

机构信息

University of Newcastle upon Tyne, Division of Oncology, Medical School, UK.

出版信息

Br J Cancer. 1990 Feb;61(2):189-91. doi: 10.1038/bjc.1990.35.

DOI:10.1038/bjc.1990.35
PMID:2178663
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1971416/
Abstract
摘要